Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1
) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of binds and activates the human inhibitory receptor TIGIT which is express...
Gespeichert in:
Veröffentlicht in: | Oncoimmunology 2019-06, Vol.8 (6), p.e1581531-e1581531 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | ) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of
in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of
binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that
also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors. |
---|---|
ISSN: | 2162-4011 2162-402X 2162-402X |
DOI: | 10.1080/2162402X.2019.1581531 |